Biogen Idec, Inc. (BIIB) Misses Q4 EPS by 6c; Guides FY13 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $240.98 -0.87%
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $1.40, $0.06 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.38 billion.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY2013 EPS of $7.15 - $7.25, versus the consensus of $7.27. Sees revs up about 10 percent.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- First Bancorp (FNLC) Tops Q3 EPS by 95c
- Southern Missouri Bancorp (SMBC) Tops Q1 EPS by 7c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
